BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity

Hormones and Cancer

Volumn 6, Issue 1, 2015, Pages 21-36

  Cabanillas, M E ^a   Patel, A ^b   Danysh, B P ^a   Dadu, R ^a   Kopetz, S ^a   Falchook, G ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Health Science Center   (United States)

^c HealthOne   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANALGESIC AGENT; ATROPINE; B RAF KINASE; B RAF KINASE INHIBITOR; BILIRUBIN; CYCLOOXYGENASE 2 INHIBITOR; DABRAFENIB; DIPHENOXYLATE; EMOLLIENT AGENT; ETRETIN; FLUOROURACIL; LACTIC ACID; LOPERAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID; SALICYLIC ACID; STEROID; SUNSCREEN; VEMURAFENIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ACTINIC KERATOSIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANALGESIA; ANOREXIA; ARTHRALGIA; BACKACHE; BILIRUBIN BLOOD LEVEL; BLURRED VISION; CANCER RESISTANCE; CARCINOGENESIS; CATARACT; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONSTIPATION; CRYOTHERAPY; CUTANEOUS MELANOMA; DEHYDRATION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSGEUSIA; DYSPLASIA; DYSPLASTIC NEVUS; ECZEMA; ELASTOSIS; EYE INFECTION; EYE PAIN; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLICLE CYST; GLAUCOMA; HAND FOOT SYNDROME; HEADACHE; HEART ARRHYTHMIA; HOSPITAL PATIENT; HUMAN; HUMIDIFIER; HYPERKERATOSIS; HYPOTENSION; KERATOACANTHOMA; KERATODERMA; KERATOSIS; LEUKOPENIA; LYMPHOCYTOPENIA; MELANOMA; MOLECULARLY TARGETED THERAPY; MYALGIA; NEUTROPHILIC DERMATOSIS; PALMOPLANTAR KERATODERMA; PANCREAS CANCER; PANNICULITIS; PATIENT REFERRAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUNCTATE KERATITIS; PYODERMA GANGRENOSUM; REVIEW; RIGOR; SARCOIDOSIS; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STEROID THERAPY; STEVENS JOHNSON SYNDROME; SUNBURN; THROMBOCYTOPENIA; THYROID CANCER; TOPICAL TREATMENT; TOXIC EPIDERMAL NECROLYSIS; TRANSIENT ACANTHOLYTIC DERMATOSIS; UVEITIS; VASCULITIS; VERRUCOUS KERATOSIS; VITILIGO; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CELL TRANSFORMATION; COLORECTAL NEOPLASMS; DISEASE MANAGEMENT; DRUG RESISTANCE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; THYROID NEOPLASMS;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE MANAGEMENT; DRUG RESISTANCE, NEOPLASM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MELANOMA; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84925511788     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-014-0207-9     Document Type: Review

References (129)

1. Siegel R, Ma J, Zou Z et al (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29
2. Durante C, Haddy N, Baudin E et al (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892–2899
3. Bible KC, Suman VJ, Molina JR et al (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11:962–972
4. Ahmed M, Barbachano Y, Riddell A et al (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 165:315–322
5. Hoftijzer H, Heemstra KA, Morreau H et al (2009) Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161:923–931
6. Hong DS, Cabanillas ME, Wheler J et al (2011) Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96:997–1005
7. Kloos RT, Ringel MD, Knopp MV et al (2009) Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675–1684
8. Gupta-Abramson V, Troxel AB, Nellore A et al (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714–4719
9. Sherman SI, Wirth LJ, Droz JP et al (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31–42
10. Cohen EE, Rosen LS, Vokes EE et al (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708–4713
11. Sherman SI, Jarzab B, Cabanillas ME et al (2011) A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 29:5503
12. Brose MS, Nutting CM, Jarzab B et al. (2014) Sorafenib in radioactive iodine–refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940):319–28.
13. Schlumberger M, Tahara M, Wirth LJ et al. (2014) A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 32 (5s; suppl): abstr LBA6008
14. Nikiforova MN, Wald AI, Roy S et al (2013) Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 98:E1852–E1860
15. Elisei R, Viola D, Torregrossa L et al (2012) The BRAF (V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97:4390–4398
16. Ricarte-Filho J, Ganly I, Rivera M et al (2012) Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid 22:575–584
17. Elisei R, Ugolini C, Viola D et al (2008) BRAF (V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93:3943–3949
18. Ugolini C, Giannini R, Lupi C et al (2007) Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 17:381–388
19. Li C, Aragon Han P, Lee KC et al (2013) Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J Clin Endocrinol Metab 98:3702–3712
20. Xing M, Alzahrani AS, Carson KA et al (2013) Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493–1501
21. Gandolfi G, Sancisi V, Piana S et al. (2014) Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma. Int J Cancer doi:10.1002/ijc.28976
22. Durante C, Puxeddu E, Ferretti E et al (2007) BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92:2840–2843
23. Smallridge RC, Ain KB, Asa SL et al (2012) American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22:1104–1139
24. Schlumberger M, Jarzab B, Elisei R, et al. (2013) Phase III randomized, double-blinded, placebo-controlled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)–refractory differentiated thyroid cancer (Dtc)—exploratory analyses of patient-reported outcomes, 83rd Annual American Thyroid Association Meeting. San Juan, PR, 2013
25. Brose M NC, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit J, Chung JW, Siedentop H, Molnar I, Schlumberger M (2013) Sorafenib in locally advanced or metastatic patients with radioactive iodine–refractory differentiated thyroid cancer: the phase III DECISION trial. J Clin Oncol 31 (suppl): abstr 4
26. Williams VL, Cohen PR, Stewart DJ (2011) Sorafenib-induced premalignant and malignant skin lesions. Int J Dermatol 50:396–402
27. Hu J, Stites EC, Yu H et al (2013) Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 154:1036–1046
28. Rebocho AP, Marais R (2013) ARAF acts as a scaffold to stabilize BRAF: CRAF heterodimers. Oncogene 32:3207–3212
29. Mooz J, Oberoi-Khanuja TK, Harms GS et al (2014) Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration. Sci Signal 7:ra73
30. Dougherty MK, Muller J, Ritt DA et al (2005) Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17:215–224
31. Avraham R, Yarden Y (2011) Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12:104–117
32. Freeman AK, Ritt DA, Morrison DK (2013) Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell 49:751–758
33. Poulikakos PI, Persaud Y, Janakiraman M et al (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 480:387–390
34. Kimura ET, Nikiforova MN, Zhu Z et al (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–1457
35. Karreth FA, DeNicola GM, Winter SP et al (2009) C-Raf inhibits MAPK activation and transformation by B-Raf (V600E). Mol Cell 36:477–486
36. Hou P, Liu D, Shan Y et al (2007) Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13:1161–1170
37. Liu Z, Hou P, Ji M et al (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106–3116
38. Tsai J, Lee JT, Wang W et al (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105:3041–3046
39. Rheault TR, Stellwagen JC, Adjabeng GM et al (2013) Discovery of dabrafenib: a selective inhibitor of raf kinases with antitumor activity against B-Raf-driven tumors. ACS Med Chem Lett 4:358–362
40. Morris V, Kopetz S: BRAF inhibitors in clinical oncology. F1000Prime Rep 5:11, 2013
41. Houben R, Becker JC, Kappel A et al (2004) Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3:6
42. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954
43. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516
44. Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365
45. Flaherty KT, Infante JR, Daud A et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694–1703
46. Richman SD, Seymour MT, Chambers P et al (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27:5931–5937
47. Kopetz S, Desai J, Chan E et al. (2010) PLX4032 in metastatic colon cancer patients with mutant BRAF tumors. J Clin Oncol 28 (15s; suppl): abstr 3534
48. Corcoran RB, Atreya CE, Falchook G, et al.: Phase 1–2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): updated efficacy and biomarker analysis. J Clin Oncol 32 (5s): abstr 3517
49. Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819
50. Kim KB, Cabanillas ME, Lazar AJ et al. (2013) Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF mutation. Thyroid 23(10):1277–83
51. Brose MS, Cabanillas ME, Cohen EE et al. (2013) An open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer positive for the BRAF V600 mutation and resistant to radioactive iodine. Proc European Cancer Congress, Amsterdam, 2013 oral abstr 28
52. Dadu R, Devine C, Hernandez M et al. (2014) Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):2086–94
53. Dadu R, Shah K, Waguespack SG et al. (2013) Efficacy and tolerability of vemurafenib in BRAFV600E positive papillary thyroid cancer. Proc 83rd Annual Meeting of the American Thyroid Association, San Juan, PR poster 227
54. Rosove MH, Peddi PF, Glaspy JA (2013) BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 368:684–685
55. Falchook GS, Long GV, Kurzrock R et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:1893–1901 doi:10.1089/thy.2014.0123
56. Chakravarty D, Santos E, Ryder M et al (2011) Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 121:4700–4711
57. Ho AL, Grewal RK, Leboeuf R et al (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368:623–632
58. Rothenberg SM, McFadden DG, Palmer E et al. (2013) Re-differentiation of radioiodine-refractory BRAF V600E-mutant thyroid carcinoma with dabrafenib: a pilot study. J Clin Oncol 31 (suppl): abstr 6025
59. Villanueva J, Vultur A, Herlyn M (2011) Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res 71:7137–7140
60. Nazarian R, Shi H, Wang Q et al (2010) Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973–977
61. Johannessen CM, Boehm JS, Kim SY et al (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968–972
62. Greger JG, Eastman SD, Zhang V et al (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11:909–920
63. Prahallad A, Sun C, Huang S et al (2012) Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 483:100–103
64. Corcoran RB, Ebi H, Turke AB et al (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227–235
65. Mao M, Tian F, Mariadason JM et al (2013) Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 19:657–667
66. Yang H, Higgins B, Kolinsky K et al (2012) Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 72:779–789
67. Montero-Conde C, Ruiz-Llorente S, Dominguez JM et al. (2013) Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Cancer Discov 3(5):520–33
68. Sos ML, Levin RS, Gordan JD et al (2014) Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Plant Cell Rep 8:1037–1048
69. Lacouture ME, Duvic M, Hauschild A et al (2013) Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18:314–322
70. Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–714
71. Wang CM, Fleming KF, Hsu S (2012) A case of vemurafenib-induced keratosis pilaris-like eruption. Dermatol Online J 18:7
72. Huang V, Hepper D, Anadkat M et al (2012) Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 148:628–633
73. Boyd KP, Vincent B, Andea A et al (2012) Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol 67:1375–1379
74. Gebhardt C, Staub J, Schmieder A et al. (2014) Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib. Acta Derm Venereol doi:10.2340/00015555-1869
75. Anforth RM, Blumetti TC, Kefford RF et al (2012) Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 167:1153–1160
76. Package insert vemurafenib (Zelboraf), Genentech
77. Larkin J, Del Vecchio M, Ascierto PA et al (2014) Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 15:436–444
78. Yorio JT, Mays SR, Ciurea AM et al. (2014) Case of vemurafenib-induced Sweet’s syndrome. J Dermatol 41(9):817–20
79. Pattanaprichakul P, Tetzlaff MT, Lapolla WJ et al (2014) Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol 41:326–328
80. Maldonado-Seral C, Berros-Fombella JP, Vivanco-Allende B et al (2013) Vemurafenib-associated neutrophilic panniculitis: an emergent adverse effect of variable severity. Dermatol Online J 19:16
81. Infante JR, Falchook G, Lawrence DP et al. (2011) Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 29 (suppl): abstr CRA8503
82. Sinha R, Edmonds K, Newton-Bishop J et al (2013) Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. J Clin Oncol 31:e320–e321
83. Monfort JB, Pages C, Schneider P et al (2012) Vemurafenib-induced neutrophilic panniculitis. Melanoma Res 22:399–401
84. Zimmer L, Livingstone E, Hillen U et al (2012) Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 148:357–361
85. Dummer R, Rinderknecht J, Goldinger SM (2012) Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 366:480–481
86. Forschner A, Zips D, Schraml C et al. (2014) Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 24(5):512–6
87. Boussemart L, Boivin C, Claveau J et al (2013) Vemurafenib and radiosensitization. JAMA Dermatol 149:855–857
88. Pulvirenti T, Hong A, Clements A et al. (2014) Acute radiation skin toxicity associated with BRAF inhibitors. J Clin Oncol pii: JCO.2013.49.0565
89. Satzger I, Degen A, Asper H et al (2013) Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol 31:e220–e222
90. Minor DR, Rodvien R, Kashani-Sabet M (2012) Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib. Melanoma Res 22:410–411
91. Wantz M, Spanoudi-Kitrimi I, Lasek A et al (2014) Vemurafenib-induced toxic epidermal necrolysis. Ann Dermatol Venereol 141:215–218
92. Alonso-Castro L, Rios-Buceta L, Vano-Galvan S et al (2013) Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma. J Am Acad Dermatol 69:e28–e29
93. Adam A, Thomas L, Bories N et al (2013) Sarcoidosis associated with vemurafenib. Br J Dermatol 169:206–208
94. Park JJ, Hawryluk EB, Tahan SR et al (2014) Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol 150:307–311
95. Gupta M, Huang V, Linette G et al (2012) Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption. Arch Dermatol 148:966–968
96. Kwon EJ, Kish LS, Jaworsky C (2009) The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol 61:522–527
97. Arnault JP, Mateus C, Escudier B et al (2012) Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 18:263–272
98. Oberholzer PA, Kee D, Dziunycz P et al (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316–321
99. Su F, Viros A, Milagre C et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207–215
100. Hatzivassiliou G, Song K, Yen I et al (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431–435
101. Poulikakos PI, Zhang C, Bollag G et al (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427–430
102. Heidorn SJ, Milagre C, Whittaker S et al (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209–221
103. Vin H, Ojeda SS, Ching G et al (2013) BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife 2:e00969
104. Long GV, Trefzer U, Davies MA et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087–1095
105. \Anforth R, Blumetti TC, Mohd Affandi A et al (2012) Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J Clin Oncol 30:e165–e167
106. Ko CJ, McNiff JM, Iftner A et al (2013) Vemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae. J Am Acad Dermatol 69:e95–e96
107. Ganzenmueller T, Hage E, Yakushko Y et al (2013) No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients. Exp Dermatol 22:725–729
108. Anforth R, Fernandez-Penas P, Long GV (2013) Cutaneous toxicities of RAF inhibitors. Lancet Oncol 14:e11–e18
109. Ascierto PA, Minor D, Ribas A et al (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31:3205–3211
110. Chu EY, Wanat KA, Miller CJ et al (2012) Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 67:1265–1272
111. Chon SY, Sambrano BL, Geddes ER (2014) Vemurafenib-related cutaneous side effects ameliorated by acitretin. J Drugs Dermatol 13:586–588
112. Alloo A, Garibyan L, LeBoeuf N et al (2012) Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 148:363–366
113. Fathi R, Kamalpour L, Gammon B et al (2013) A novel treatment approach for extensive, eruptive, cutaneous squamous cell carcinomas in a patient receiving BRAF inhibitor therapy for metastatic melanoma. Dermatol Surg 39:341–344
114. LaPresto L, Cranmer L, Morrison L et al (2013) A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil. JAMA Dermatol 149:279–281
115. Cohen PR, Bedikian AY, Kim KB (2013) Appearance of new vemurafenib-associated melanocytic nevi on normal-appearing skin: case series and a review of changing or new pigmented lesions in patients with metastatic malignant melanoma after initiating treatment with vemurafenib. J Clin Aesthet Dermatol 6:27–37
116. Zimmer L, Hillen U, Livingstone E et al (2012) Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375–2383
117. Dalle S, Poulalhon N, Debarbieux S et al (2013) Tracking of second primary melanomas in vemurafenib-treated patients. JAMA Dermatol 149:488–490
118. Goppner D, Muller J, Kruger S, et al. (2014) High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib. Acta Derm Venereol 94(5):517–20
119. Trinh VA, Davis JE, Anderson JE et al (2014) Dabrafenib therapy for advanced melanoma. Ann Pharmacother 48:519–529
120. Package insert dabrafenib (Tafinlar), GlaxoSmithKline
121. Wolf SE, Meenken C, Moll AC et al (2013) Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. BMC Cancer 13:561
122. Joshi L, Karydis A, Gemenetzi M et al (2013) Uveitis as a result of MAP Kinase pathway inhibition. Case Rep Ophthalmol 4:279–282
123. Callahan MK, Rampal R, Harding JJ et al (2012) Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316–2321
124. Chapman P, Metz D, Sepulveda AR (2012) Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib. Society for Melanoma Research Congress, Los Angeles, CA
125. Andrews MC, Behren A, Chionh F et al (2013) BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol 31:e448–e451
126. Carlino MS, Kwan V, Miller DK, et al. (2014) New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. J Clin Oncol doi:10.1200/JCO.2013.51.5783
127. Sun C, Wang L, Huang S et al (2014) Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma. Nature 508:118–122
128. Wilson TR, Fridlyand J, Yan Y et al (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505–509
129. Cabanillas ME, Dadu R, Sturgis EM (2014) Neoadjuvant vemurafenib (VEM) for locally advanced papillary thyroid cancer (PTC) harboring BRAF V600E mutation: a case report. Proc American Association of Clinical Endocrinologists 23rd Annual Scientific & Clinical Congress, abstr no. 1156